F Stephen Hodi
MD
Director, Melanoma Center and Center for Immuno-Oncology
👥Biography 个人简介
F Stephen Hodi is a leading melanoma immunotherapy investigator who has been central to the clinical development of relatlimab, the first approved LAG-3-targeting antibody. His work on the RELATIVITY-047 trial demonstrated the benefit of nivolumab-relatlimab combination in melanoma. He has advanced biomarker-driven approaches to immune checkpoint therapy selection.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 F Stephen Hodi 的研究动态
Follow F Stephen Hodi's research updates
留下邮箱，当我们发布与 F Stephen Hodi（Dana-Farber Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment